Altuviiio May See Rapid Uptake Upon European Approval In Hemophilia A

Pediatric Data Clears Path For EMA Filing

 
• By Alaric DeArment

Sanofi announced results from its XTEND-Kids trial, clearing the last requirement before an anticipated second half filing for Altuviiio’s approval with the EMA.

Sanofi announced results of the Phase III XTEND-Kids study of Factor VIII replacement therapy Altuviiio • Source: Shutterstock

More from Clinical Trials

More from R&D